Press Room

Press Release / May 04, 2020

Hovione Announces the Appointment of Jean-Luc Herbeaux as Chief Operating Officer

Effective May 1st, 2020

Loures, Portugal, May 4, 2020 – Hovione announced today the appointment of Dr. Jean-Luc Herbeaux as Chief Operating Officer (COO), effective May 1st, 2020. Dr. Herbeaux held, over the past 20 years, multiple high-level leadership positions at Evonik, bringing to Hovione a proven commitment to develop a successful and globally active business. Based in Lisbon, Portugal, Dr. Herbeaux will work directly with Mr. Guy Villax, Hovione’s Chief Executive Officer, in executing the company’s strategy and vision.

“We are delighted to welcome Dr. Herbeaux to Hovione. Jean-Luc will oversee all aspects of Hovione’s business operations and I see the creation of this position as another major steppingstone in our journey to become an even stronger company. Our new structure will develop synergies and increase operational efficiency, which will benefit the customers. I am sure this appointment will bring great things to all stakeholders – patients, customers, and team members as well as shareholders. Our leadership team is now well positioned to accelerate our long-term growth plans”, said Mr. Guy Villax.

“I am really excited to take on the COO role at Hovione. Hovione is a company with a great vision, great people and great science and it has an important role in the pharma industry. I look forward to working with Guy and the Hovione Team to bring this already successful company to new heights”, said Dr. Jean-Luc Herbeaux.

Prior to joining Hovione, Dr. Herbeaux headed the Health Care Business Line of Evonik, where he repositioned the business by driving an intentional, sustainable, and profitable growth agenda. His earlier postings, which included senior positions in Europe and Asia, allowed him to develop strong experience in management of complex global organizations.

 

 

About Hovione
Hovione is an international company with 60 years of experience as a Contract Development and Manufacturing Organization (CDMO) and is currently a fully integrated supplier offering services for drug substance, drug product intermediate and drug product. With four FDA inspected sites in the USMacauIreland, and Portugal, and development laboratories in Lisbon and New Jersey, USA, the company provides branded pharmaceutical customers services for the development and cGMP-compliant manufacture of innovative drugs including highly potent compounds. For generic pharmaceutical customers the company offers niche API products. Hovione also provides proprietary product development and licensing opportunities for drug products. In the inhalation area, Hovione is the only independent company offering a complete range of services.

Also in the Press Room

See All

Hovione’s Eunice Costa Shares Insights on Inhaled Medicine Formulation in Pharmaceutical Technology eBook The demand for efficient inhalation therapies is higher than ever. At Hovione we are focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes.  To learn more about or work, do not miss the contribution of Eunice Costa, our R&D Director for Inhalation & Advanced Drug Delivery, in the latest Pharmaceutical Technology eBook – “Trends in Formulation”.  In her interview, Eunice discusses key challenges and considerations in formulating inhaled medicines, emphasizing the importance of excipient selection, device compatibility, and patient-centric design for successful drug delivery to the lungs. With respiratory diseases at the forefront, especially following the COVID-19 pandemic, the demand for efficient inhalation therapies is higher than ever. Eunice sheds light on how Hovione is tackling these demands by focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes. Explore Eunice Costa’s full insights on this crucial area of drug development in Pharmaceutical Technology's September 2024 eBook. This resource provides an in-depth look into the complexities of inhaled drug formulations and the exciting innovations shaping the future of respiratory treatments.   Read the full article at Pharmaceutical Technology eBook Read the Trends in Formulation eBook at PharmTech  

Article

Formulating Inhaled Medicines

Sep 24, 2024

Lisbon, Portugal – Hovione, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, Hovione joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At Hovione, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of Hovione. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” Hovione will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with Hovione’s sustainability ambitions.  Hovione remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

Hovione Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024